Avasarala, Jagannadha. “Anti-CD20 Cell Therapies in Multiple Sclerosis—A Fixed Dosing Schedule for Ocrelizumab Is Overkill”. Drug Target Insights 11, no. 1 (November 8, 2017). Accessed July 3, 2024. https://journals.aboutscience.eu/index.php/dti/article/view/1367.